HIGHLIGHTS
- who: Can J Neurol Sci. et al. from the AbbVie Inc, Marlow, Buckinghamshire, UK have published the paper: OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study, in the Journal: (JOURNAL) of January/29,/2019
- what: The target population size for this study, which was collected using a convenience sample based on clinical and practical considerations, was 200 participants. Assuming a dropout rate of ~10%, it was anticipated that the remaining sample size would be sufficient to meet the study objectives. For individuals that discontinued the study, their last visit prior to discontinuation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.